FDA accepts review for ANGLE’s Parsortix system for metastatic breast cancer
System captures and harvests intact circulating tumour cells for analysis
Read More
Tag: metastatic breast cancer
AZ/Daiichi’s breast cancer drug gets US priority review
AstraZeneca and Daiichi Sankyo’s trastuzumab deruxtecan has taken a step closer to US approval having been accepted for priority review by the US Food and Drug Administration (FDA) for breast cancer.
Read More
Novartis’ Kisqali hit with NICE rejection
The drug is typically used with fulvestrant to treat people with advanced breast cancer.
Read More
Lynparza gains EU approval for type of metastatic breast cancer
The approval makes it the first PARP inhibitor approved in Europe for the disease.
Read MorePfizer’s Ibrance extended for use in men by FDA
Pfizer’s Ibrance will now be available to male patients with metastatic breast cancer.
Read More
NICE approval for Verzenios in metastatic breast cancer
The National Institute for Health and Care Excellence has recommended Eli Lilly’s Verzenios in combination with an aromatase inhibitor as treatment option for locally advanced or metastatic breast cancer
Read More
- Strong clinical data for Breye lead asset danegaptide
- EHP Awards triumph
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
